Kuria to present at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2025
- Keith Ward
- 6 days ago
- 1 min read
- Kuria to present positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease
Kuria Therapeutics, a pharmaceutical firm focused on creating innovative Nrf2 activators for eye diseases, is set to present a scientific poster at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. This prominent ophthalmology conference will take place from May 4 to May 8, 2025, in Salt Lake City, UT.
Poster: SCO-116, a novel small-molecule NRF2 activator, potently induces NQO1 in multiple monkey ocular tissues, including retina, after topical ocular administration
Date: May 6, 2025
Presenter: Keith Ward, PhD, Chief Executive Officer, Kuria
Downloadable versions of these posters will be available on Kuria's website following their presentation at the ARVO meeting.
The ARVO Annual Meeting is the leading international scientific conference focused on vision research, highlighting the newest advancements and innovations in ophthalmology. Alongside the poster presentation, Kuria's team will be present in Salt Lake City for individual meetings throughout the event.
About Kuria Therapeutics, Inc.:
Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.